pISSN 2636-0004eISSN 2636-0012
pISSN 2636-0004Clinical Characteristics of the Patients
| Characteristic | Value |
|---|---|
| Total follow-up (mo) | 23 (1.5–96) |
| Number of received CT cycles | 6 (2–8) |
| Follow up until recurrence (mo) | 14 (4–49) |
| Adjuvant CT | |
| Present | 71 (68.3) |
| Absent | 33 (31.7) |
| Adjuvant CT protocol | |
| Folfox | 33 (31.7) |
| FLOT | 5 (4.8) |
| Capox | 12 (11.5) |
| Cisplatin-Capecitabine | 9 (8.7) |
| Other | 12 (11.5) |
| Adjuvant RT | |
| Present | 39 (37.5) |
| Absent | 65 (62.5) |
| Recurrence | |
| Present | 23 (22.1) |
| Absent | 81 (77.9) |
| Location of recurrence | |
| Lungs | 3 (2.9) |
| Brain | 1 (1.0) |
| Liver | 6 (5.8) |
| Bones | 1 (1.0) |
| Local | 3 (2.9) |
| Ovaries | 2 (1.9) |
| Peritoneum | 4 (3.8) |
| Diffuse | 3 (2.9) |
| Survival status | |
| Death | 34 (32.7) |
| Survival | 70 (67.3) |
Values are presented as mean (range) or number (%)
CT, chemotherapy; RT, radiotherapy; Folfox, folinic acid (leucovorin, FOL), fluorouracil (5-FU, F), oxaliplatin (Eloxatin, OX); FLOT, fluorouracil (5-FU, F), leucovorin (L), oxaliplatin (O), docetaxel (D); Capox, capecitabine and oxaliplatin